Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 3;25(21):5096.
doi: 10.3390/molecules25215096.

Characterization of Ciprofloxacin-Bismuth-Loaded Antibacterial Wound Dressing

Dorota Kowalczuk  1 , Małgorzata Miazga-Karska  2 , Agata Gładysz  1 , Paweł Warda  1 , Agnieszka Barańska  3 , Bartłomiej Drop  3
Affiliations

Characterization of Ciprofloxacin-Bismuth-Loaded Antibacterial Wound Dressing

Dorota Kowalczuk et al. Molecules. .

Abstract

The research was focused on developing a potentially antibacterial wound dressing made of polyurethane foam and loaded with bismuth-ciprofloxacin (Cip-Bi). The Cip-Bi chemical structure was confirmed by Fourier transform infrared spectroscopic (FTIR) analysis. The sought after antibacterial wound dressing was obtained by modification of the raw dressing with an iodine or bromine solution and subsequently with a Cip-Bi hydrogel. The amount of Cip-Bi loaded into the dressing matrix was determined indirectly on the basis of the differences in Cip-Bi concentrations, before and after the modification process, and the determination was performed with the HPLC (high-performance liquid chromatography) method. The modified dressing was found to have a two-step release of Cip-Bi, a feature helpful in the treatment of locally infected wounds and prevention of secondary bacterial infection. The zone of inhibition test against the selected Gram-positive and Gram-negative bacteria confirmed the antibacterial activity of the Cip-Bi-modified dressing. Preliminary tests conducted so far have been indicative of the Cip-Bi dressing's relatively high activity against the tested organisms.

Keywords: antimicrobial delivery; antimicrobial dressing; ciprofloxacin-bismuth complex; wound dressing; wound infection.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Scheme 1
Scheme 1
Synthesis and activity of ciprofloxacin-bismuth-loaded dressing.
Figure 1
Figure 1
Fourier transform infrared (FTIR) spectra obtained for ciprofloxacin (Cip) as hydrochloride and ciprofloxacin-bismuth complex (Cip-Bi).
Figure 2
Figure 2
UV absorption spectra of ciprofloxacin (A) and ciprofloxacin-Bi complex (B) as a function of the concentration in μg/mL: 5 (back line), 10 (red line), 20 (blue line).
Figure 3
Figure 3
Suggested three-dimensional (3D)-structure for ciprofloxacin-bismuth complex.
Figure 4
Figure 4
The amount of the ciprofloxacin-bismuth (Cip-Bi) introduced into the dressing sample (colorless bar) and released from the dressing sample (black bar). (a) S6—bromine-activated, Cip-Bi hydrogel-loaded dressing; (b) S7—iodine-activated, Cip-Bi hydrogel-loaded dressing.
Figure 5
Figure 5
A representative graph comparing the antibacterial activity of the ciprofloxacin-bismuth (Cip-Bi) dressing samples: Sample 4 (bromine-activated, hydrogel-loaded dressing); Sample 5 (iodine-activated, hydrogel-loaded dressing); Sample 6 (bromine-activated, Cip-Bi hydrogel-loaded dressing); Sample 7 (iodine-activated, Cip-Bi hydrogel-loaded dressing) against the tested, reference (ref.) and clinical strains of bacteria (c.i.w.—clinical isolates from infected wounds).
Figure 6
Figure 6
Exemplary photographs showing the antibacterial activity of the tested dressing: S6—modified Br2/Cip-Bi hydrogel and S7—modified I2/Cip-Bi hydrogel in relation to the untreated dressing (control sample S1) against S. aureus c.i.w (A) and E. coli c.i.w (B) strains.
See this image and copyright information in PMC

References

    1. Guz-Regner K., Komarnicka U.K., Futoma-Kołoch B., Wernecki M., Cal M., Kozieł S., Ziółkowska A., Bugla-Płoskońska G. Antibacterial activity and action mode of Cu(I) and Cu(II) complexes with phosphines derived from fluoroquinolone against clinical and multidrug-resistant bacterial strains. J. Inorg. Biochem. 2020;210:111124. doi: 10.1016/j.jinorgbio.2020.111124. - DOI - PubMed
    1. Laponogov I., Sohi M.K., Veselkov D.A., Pan X.-S., Sawhney R., Thompson A.W., McAuley K.E., Fisher L.M., Sanderson M.R. Structural insight into the quinolone–DNA cleavage complex of type IIA topoisomerases. Nat. Struct. Mol. Biol. 2009;16:667–669. doi: 10.1038/nsmb.1604. - DOI - PubMed
    1. Tse-Dinh Y.-C. Bacterial topoisomerase I as a target for discovery of antibacterial compounds. Nucleic Acids Res. 2008;37:731–737. doi: 10.1093/nar/gkn936. - DOI - PMC - PubMed
    1. Sharma R.C., Giri P.P., Kumar D., Neelam J. Synthesis, spectral and antimicrobial activity of mixed ligand complexes of Co(II), Ni(II), Cu(II) and Zn(II) with N,O and S donor ligands. J. Chem. Pharm. Res. 2012;4:1969–1973.
    1. Turel I. The interactions of metal ions with quinolone antibacterial agents. Co-Ord. Chem. Rev. 2002;232:27–47. doi: 10.1016/S0010-8545(02)00027-9. - DOI

MeSH terms